Paradigm Biopharmaceuticals (ASX:PAR) Accounts Payable: A$4.44 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
27 GF Score
Price A$0.18
! 4 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Accounts Payable?

Paradigm Biopharmaceuticals ASX:PAR 27 Accounts Payable is A$4.44 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Paradigm Biopharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2025 was A$4.44 Mil.

Paradigm Biopharmaceuticals's quarterly Accounts Payable increased from Dec. 2024 (A$0.58 Mil) to Jun. 2025 (A$2.74 Mil) and increased from Jun. 2025 (A$2.74 Mil) to Dec. 2025 (A$4.44 Mil).

Paradigm Biopharmaceuticals's annual Accounts Payable declined from Jun. 2023 (A$12.16 Mil) to Jun. 2024 (A$2.82 Mil) and declined from Jun. 2024 (A$2.82 Mil) to Jun. 2025 (A$2.74 Mil).

Paradigm Biopharmaceuticals Accounts Payable Related Terms

Paradigm Biopharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Accounts Payable Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.99 7.09 12.16 2.82 2.74

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.99 2.82 0.58 2.74 4.44
ASX:PAR
27GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$4.44 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Accounts Payable of A$4.44 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Accounts Payable too high?
Paradigm Biopharmaceuticals' current Accounts Payable is A$4.44 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Accounts Payable compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Accounts Payable of A$4.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Accounts Payable is A$4.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Accounts Payable of A$4.44 Mil. The current Accounts Payable is A$4.44 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Accounts Payable is A$4.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score

Get the complete analysis for ASX:PAR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price